Ondine Biomedical Inc.
OBI · AIM · Health Care · mcap £55m · 9.7p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 30 Sep 26 | Capital Access Window - Ondine Biomedical Inc.
COMMON SHARES OF NO PAR VALUE, FULLY PAID (CDI) |
+0.0% | |
| 30 Sep 26 | Capital Access Window
Ondine announces equity fundraise under AIM Capital Access Window, trading paused. |
+0.0% | |
| 30 Sep 26 | Results | 2026 Interim Results & Post-Period Momentum
H1 2026 revenue up 23% to $1.25m; Phase 3 LANTERN trial met primary endpoint with 40.5% relative reduction in surgical site infection risk. |
+0.0% |
| 29 Sep 26 | Ondine and Mela Advance NHS ICU Market Access
Ondine partners with Mela Solutions to evaluate Steriwave nasal photodisinfection across NHS ICUs targeting 6-10 hospitals in year one. |
+0.0% | |
| 23 Sep 26 | Steriwave Deploys in 5 Southern Ontario Hospitals
Five Southern Ontario hospitals to deploy Steriwave across approximately 5,000 annual surgical procedures. |
+0.0% | |
| 10 Sep 26 | Results | Investor Presentation of Phase 3 Topline Results
Ondine Biomedical to Present Topline Results from Phase 3 LANTERN Trial |
+2.3% |
| 07 Sep 26 | Largest Private Mexican Network Pilots Steriwave
Mexico's largest private hospital network pilots Steriwave nasal photodisinfection at two flagship facilities on commercial basis. |
+0.0% | |
| 01 Sep 26 | Results | Positive Topline Results in US Phase 3 Study
Phase 3 LANTERN trial met primary endpoint with 40% relative reduction in surgical site infections versus standard care alone. |
+2.1% |
| 30 Jul 26 | Major Scottish Hospital Adopts Steriwave
NHS Golden Jubilee, Scotland's largest hip and knee replacement centre, adopts Steriwave nasal photodisinfection. |
+0.0% | |
| 13 Jul 26 | Update on US Phase 3 Pivotal Study
LANTERN Phase 3 pivotal study topline results expected within approximately six weeks. |
−6.9% | |
| 01 Jul 26 | Keynote Address at 8th Annual Photodynamic Day
Dr. Nicolas Loebel delivered keynote address at 8th Annual Photodynamic Day in Istanbul on Ondine's photodisinfection technology. |
+2.7% | |
| 30 Jun 26 | Leeds drops SSI 78% over Mupirocin with Steriwave
Published Leeds study shows Steriwave reduced surgical site infections by 78% versus mupirocin in skull-base surgery. |
+1.7% | |
| 22 Jun 26 | Update on US Phase 3 Pivotal Study
Phase 3 LANTERN study endpoint adjudication complete; top-line results expected within one to two weeks. |
+1.7% | |
| 18 Jun 26 | Leeds Drops SSIs by 78.5% in Complex Brain Surgery
Ondine's nasal photodisinfection reduced surgical site infections by 78.5% in complex brain surgery at Leeds Teaching Hospitals. |
+0.0% | |
| 04 Jun 26 | Results | 2025 Full Year Results and Annual Report
2025 revenue up 29% to $2.6m CAD; Phase 3 LANTERN trial patient enrolment completed with top-line results expected Spring 2026. |
−3.4% |
| 26 May 26 | Steriwave ICU Study Outcomes Presented at CSRT2026
SMURF feasibility study of nasal photodisinfection presented at CSRT2026 conference, showing exploratory reductions in pneumonia rates. |
+0.0% | |
| 30 Apr 26 | Ondine Presented Steriwave Data at IPC 2026
Ondine presented Steriwave nasal photodisinfection clinical data at IPC 2026 conference; product classified as NHS Innovation Product. |
+0.0% | |
| 29 Apr 26 | Fundraise | Result of Fundraise & TVR
Ondine raised £5 million through placing and subscription at 12p per share, issuing 41.67 million new shares. |
−6.0% |
| 28 Apr 26 | Fundraise | Proposed c.£5 million (C$9.23 million) Fundraise
Ondine raises approximately £5 million via placing and subscription at 12 pence per share. |
+0.0% |
| 27 Apr 26 | ICU Study to be Presented at 2026 CACCN Conference
ICU study of Steriwave nasal photodisinfection accepted for oral presentation at Canadian Critical Care Nursing Conference. |
+0.0% | |
| 23 Apr 26 | Marked Reduction in SSIs at Ottawa Heart Institute
University of Ottawa Heart Institute reports marked reduction in surgical site infections using Ondine's Steriwave nasal photodisinfection. |
+4.2% | |
| 22 Apr 26 | Two Abstracts Accepted at World Congress
Two abstracts accepted for poster presentation at World Congress on Infectious Diseases in June 2026. |
+4.3% | |
| 14 Apr 26 | Steriwave ICU Study Shows 39.5% Pneumonia Drop
Royal Columbian Hospital study shows Steriwave nasal photodisinfection reduces ICU pneumonia rates by 39.5%. |
+2.3% | |
| 13 Apr 26 | Business Update
Completed LANTERN Phase 3 trial enrolment with 5,000 patients; 29% revenue growth in 2025; expanding manufacturing capacity. |
+0.0% | |
| 08 Apr 26 | ICU Study Accepted for Publication
Pilot study of nasal photodisinfection in ICU setting accepted for publication in Journal of Critical Care. |
+4.8% | |
| 10 Mar 26 | Ondine Provides Update on US Phase 3 Pivotal Study
LANTERN Phase 3 study 93% enrolled, on track for Spring 2026 top-line results. |
+7.3% | |
| 25 Feb 26 | Share Issuance for ICU Study Submission
Ondine issues 1.18m shares at 9.75p following submission of ICU study results for publication. |
+2.5% | |
| 06 Feb 26 | Ondine and Mid Yorks Win National Award
Ondine and Mid Yorkshire NHS Trust win national award for reducing surgical site infections using Steriwave technology. |
+0.0% | |
| 02 Feb 26 | Steriwave Up for 2025 “Product of the Year” Award
Steriwave shortlisted as finalist for 2025 Bionow Product of the Year Award. |
+0.0% | |
| 27 Jan 26 | Expanding Steriwave Use Across Vancouver Island
Cowichan District Hospital in British Columbia adopts Steriwave for orthopedic pre-surgical infection prevention. |
+0.0% | |
| 22 Jan 26 | Steriwave Expands into ENT Surgery in Spain
Steriwave nasal photodisinfection technology deployed with leading ENT specialist group in Spain. |
+3.1% | |
| 13 Jan 26 | New Independent Study Supports Photodisinfection
Independent study supports photodisinfection technology for nasal decolonization; separate evaluations report up to 70% reduction in surgical site infections. |
+0.0% | |
| 23 Dec 25 | Finalist for 2nd National Award for SSI reduction
Ondine and Mid Yorkshire Teaching NHS Trust shortlisted for national award for reducing surgical site infections using Steriwave nasal photodisinfection. |
−4.4% | |
| 22 Dec 25 | First German Hospital Pilots Steriwave
Ondine announces research collaboration with LMU University Hospital Munich to pilot Steriwave photodisinfection in ENT patients. |
−6.5% | |
| 16 Dec 25 | Ondine shortlisted for HSJ Partnership Award
Ondine shortlisted for HSJ Partnership Award for Steriwave nasal decolonisation technology reducing surgical infections. |
−4.9% | |
| 27 Oct 25 | Results | Topline Results Significant in Steriwave ICU Study
Steriwave nasal photodisinfection achieved significant pathogen reduction in ICU pilot study at Royal Columbian Hospital. |
+4.0% |
Company filings. Not investment advice.